Mass. Biotechs Have Much At Stake, As Trump Calls Drug Prices A 'Major Priority'
As price-control efforts go, the president's latest plan is "fairly business-friendly," says Boston College health economist Sam Richardson. |!| Boston
As price-control efforts go, the president's latest plan is "fairly business-friendly," says Boston College health economist Sam Richardson. |!| Boston